Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AAV1/SERCA2a gene transfer in advanced heart failure patients with LVAD
2007-002809-48Phase 2Terminated
- Sponsor
- Imperial College London and Imperial College Healthcare NHS Trust
- Start
- Mar 2013
- Modality
- Viral Vectors → Gene Addition/Replacement → Gene Therapies
- Countries
- 1
01
Overview
Phase 2 trial of AAV1/SERCA2a in chronic heart failure (CHF) and heart failure (HF) (4 arms), sponsored by Imperial College London and Imperial College Healthcare NHS Trust. Primary endpoint: Overall safety and feasibility. Started Mar 2013; status: terminated.
02
Drugs
AAV1/SERCA2a
03
Conditions
chronic heart failure (CHF)heart failure (HF)
Beyond the preview
Go deeper on 2007-002809-48.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-002809-48.